^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PSCA Expression

    i
    Other names: PSCA, Prostate Stem Cell Antigen 2, PRO232
    Entrez ID:
    8000
    Associations

    News

    Trials
    over1year
    PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=21, Recruiting, City of Hope Medical Center | Trial completion date: Jul 2028 --> Nov 2026 | Trial primary completion date: Aug 2027 --> Nov 2026
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Metastases
    |
    PSCA (Prostate Stem Cell Antigen 2)
    |
    PSCA Expression
    |
    MB-105
    almost2years
    Significance of PSCA as a novel prognostic marker and therapeutic target for cancer. (PubMed, Cancer Cell Int)
    PSCA has several genetic variants that seem to play a significant role in cancer susceptibility in some tissues, so identifying the characteristics of this antigen and its relationship and variants with clinical features can be beneficial in concomitant cancer therapy and diagnosis, as theranostic tools. In this study, we will review the alteration of the PSCA expression and its polymorphisms and evaluate its clinical and theranostics significance in various cancers.
    Review • Journal
    |
    PSCA (Prostate Stem Cell Antigen 2)
    |
    PSCA Expression
    2years
    PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=21, Recruiting, City of Hope Medical Center | Trial completion date: Nov 2025 --> Jul 2028 | Trial primary completion date: Nov 2025 --> Aug 2027
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Metastases
    |
    PSCA (Prostate Stem Cell Antigen 2)
    |
    PSCA Expression
    |
    MB-105
    2years
    PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=21, Recruiting, City of Hope Medical Center | Phase classification: P1b --> P1 | Trial completion date: Feb 2026 --> Nov 2025 | Trial primary completion date: Feb 2026 --> Nov 2025
    Phase classification • Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Metastases
    |
    PSCA (Prostate Stem Cell Antigen 2)
    |
    PSCA Expression
    |
    MB-105
    over2years
    Exploring the Tumor-Suppressing Potential of PSCA in Pancreatic Ductal Adenocarcinoma. (PubMed, Cancers (Basel))
    The anti-tumor effects of extracellular PSCA complemented those of chemotherapeutic agents like Irinotecan, 5-Fluorouracil, and Oxaliplatin. PSCA expression increased in a conditioned medium derived from PBMCs and T lymphocytes. This study unveils the paradoxical anti-PDAC potential of PSCA, hinting at the dual roles of oncoproteins like PSCA in PDAC suppression.
    Journal
    |
    MSLN (Mesothelin) • PSCA (Prostate Stem Cell Antigen 2)
    |
    PSCA Expression
    |
    5-fluorouracil • oxaliplatin • irinotecan
    over2years
    PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1b, N=21, Recruiting, City of Hope Medical Center | Initiation date: Jul 2023 --> Oct 2023
    Trial initiation date • CAR T-Cell Therapy • Metastases
    |
    PSCA (Prostate Stem Cell Antigen 2)
    |
    PSCA Expression
    |
    MB-105
    over2years
    PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, City of Hope Medical Center | Trial primary completion date: Nov 2023 --> Aug 2022
    Trial primary completion date • CAR T-Cell Therapy • Metastases
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • PSCA (Prostate Stem Cell Antigen 2)
    |
    PSCA Expression
    |
    cyclophosphamide • fludarabine IV • MB-105
    over2years
    Cross-phenotype association analysis of gastric cancer: in-silico functional annotation based on the disease-gene network. (PubMed, Gastric Cancer)
    These findings identified seven GC-associated genes exhibiting a cross-association with GFR, BUN, and UA.
    Journal
    |
    MUC1 (Mucin 1) • PSCA (Prostate Stem Cell Antigen 2) • TRIM46 (Tripartite Motif Containing 46)
    |
    PSCA Expression
    over2years
    PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=30 --> 15
    Enrollment closed • Enrollment change • CAR T-Cell Therapy • Metastases
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • PSCA (Prostate Stem Cell Antigen 2)
    |
    PSCA Expression
    |
    cyclophosphamide • fludarabine IV • MB-105
    over2years
    Preclinical Characterization of the Lu-Labeled Prostate Stem Cell Antigen (PSCA)-Specific Monoclonal Antibody 7F5. (PubMed, Int J Mol Sci)
    Accordingly, SPECT/CT images revealed a high tumor-to-background ratios from 16 h to 7 days after administration of [Lu]Lu-CHX-A″-DTPA-7F5. Consequently, [Lu]Lu-CHX-A″-DTPA-7F5 represents a promising candidate for imaging and in the future also for radioimmunotherapy.
    Preclinical • Journal • IO biomarker
    |
    PSCA (Prostate Stem Cell Antigen 2)
    |
    FOLH1 expression • PSCA Expression
    almost3years
    PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1b, N=21, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Initiation date: Sep 2023 --> May 2023
    Enrollment open • Trial initiation date • CAR T-Cell Therapy • Metastases
    |
    PSCA (Prostate Stem Cell Antigen 2)
    |
    PSCA Expression
    |
    MB-105
    almost3years
    Final results from phase I study of PSCA-targeted chimeric antigen receptor (CAR) T cells in patients with metastatic castration resistant prostate cancer (mCRPC). (ASCO 2023)
    12(86%) had previously been treated with chemotherapy; 9 received two taxanes and 3 docetaxel only...The protocol was amended to reduce the LD dose to 300 mg/m2 cyclophosphamide D1-3... PSCA-CAR T cells have anti-cancer activity in mCRPC with DLT of cystitis. LD was required for greater expansion and activity; lower dose LD improved toxicity without clear negative impact on expansion. Clinical trial information: NCT03873805.
    Clinical • P1 data • Metastases
    |
    PSCA (Prostate Stem Cell Antigen 2)
    |
    PSCA Expression
    |
    docetaxel • cyclophosphamide • MB-105